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ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to provide a scientific opinion on a health claim pursuant to Article 13 of Regulation (EC) No 
1924/2006 in the framework of further assessment related to polyphenols in olive and maintenance of normal 
blood HDL-cholesterol concentrations. The food constituent, polyphenols in olive (olive fruit, olive mill waste 
waters or olive oil, Olea europaea L. extract and leaf) standardised by their content of hydroxytyrosol and its 
derivatives (e.g. oleuropein complex), that is the subject of the health claim is sufficiently characterised. The 
claimed effect, maintenance of normal blood HDL-cholesterol concentrations, which is eligible for further 
assessment, is a beneficial physiological effect. The proposed target population is the general population. No 
evidence from which conclusions could be drawn for the scientific substantiation of the claim, in addition to the 
Panel’s earlier opinion, was provided. The Panel considers that no data were submitted which would require a 
reconsideration of the conclusions expressed in its previous opinion, in which it concluded that the evidence 
provided was insufficient to establish a cause and effect relationship between the consumption of olive oil 
polyphenols (standardised by the content of hydroxytyrosol and its derivatives) and maintenance of normal blood 
HDL cholesterol concentrations. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to provide a scientific opinion on a list of health claims pursuant to 
Article 13 of Regulation (EC) No 1924/2006. The Commission has agreed with EU Member States 
that a certain number of Article 13 health claims would be eligible for further assessment by EFSA in 
order to be able to take a final decision on whether or not to include these claims in the list of 
permitted health claims. This opinion addresses the scientific substantiation of a health claim in 
relation to polyphenols in olive and maintenance of normal blood HDL-cholesterol concentrations. 
The assessment is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims, references that EFSA has received from Member States or directly from 
stakeholders and the additional information provided by the competent Authority of Germany for 
further assessment of this claim. 
The food constituent that is the subject of the health claim is polyphenols in olive. The Panel 
considers that polyphenols in olive (olive fruit, olive mill waste waters or olive oil, Olea europaea L. 
extract and leaf) standardised by their content of hydroxytyrosol and its derivatives (e.g. oleuropein 
complex) are sufficiently characterised. 
The claimed effect, which is eligible for further assessment, relates to the maintenance of normal 
blood HDL-cholesterol concentrations. The proposed target population is the general population. The 
Panel considers that maintenance of normal blood HDL-cholesterol concentrations (without 
increasing LDL-cholesterol concentrations) is a beneficial physiological effect. 
In the framework of further assessment nine human intervention and four animal studies were 
provided. The Panel notes that none of these studies allowed conclusions to be drawn for the 
scientific substantiation of the claim owing to the fact that the content of hydroxytyrosol or its 
derivatives (e.g. oleuropein complex) in the olive oils administered in the studies was not reported, 
that studies showed major methodological limitations, and that results from rat studies could not be 
extrapolated to humans because of differences in lipid metabolism between these two species. 
The Panel notes that no evidence from which conclusions could be drawn for the scientific 
substantiation of the claim, in addition to the Panel’s earlier opinion, was provided. 
The Panel considers that no data were submitted which would require a reconsideration of the 
conclusions expressed in its previous opinion, in which it concluded that the evidence provided was 
insufficient to establish a cause and effect relationship between the consumption of olive oil 
polyphenols (standardised by the content of hydroxytyrosol and its derivatives) and maintenance of 
normal blood HDL-cholesterol concentrations. 
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INTRODUCTION 
The Commission has agreed with EU Member States that a certain number of Article 13 health claims 
would be eligible for further assessment by EFSA in order to be able to take a final decision on 
whether or not to include these claims in the list of permitted health claims. These claims include 
already assessed claims related to micro-organisms which the Panel considered to be not sufficiently 
characterised and claims for which the NDA Panel concluded that there was insufficient evidence to 
establish a cause and effect relationship between the consumption of the food and the claimed effect. 
Following an opinion of the NDA Panel pursuant to Article 13 of Regulation (EC) No 1924/2006
5
 in 
which the Panel concluded that the evidence provided was insufficient to establish a cause and effect 
relationship between polyphenols in olive and maintenance of normal blood HDL-cholesterol 
concentrations (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2011), EFSA 
received additional information from the competent Authority of Germany for further assessment of 
this claim.  
ASSESSMENT 
1. Characterisation of the food/constituent (ID 1639) 
The food constituent that is the subject of the health claims is polyphenols in olive (olive fruit, olive 
mill waste waters or olive oil, Olea europaea L. extract and leaf) standardised by their content of 
hydroxytyrosol and its derivatives (e.g. oleuropein complex).  
Polyphenols comprise a very wide group (several thousands of compounds) of plant secondary 
metabolites including flavonoids, isoflavonoids, phenolic acids, proanthocyanidins and other tannins, 
and lignans with different biological activities. The major polyphenols in olive oil are phenolic 
alcohols (e.g. hydroxytyrosol and tyrosol), secoiridoids (e.g. oleuropein) and lignans 
(e.g. pinoresinol). Table olives typically contain hydroxytyrosol, tyrosol, caffeoylquinic acid, 
verbacoside, luteolin and rutin. Hydroxytyrosol, a major polyphenol typically present in olives, is also 
present in olive mill waste water. In nature, hydroxytyrosol is found in olives also in the form of a 
glucoside of its elenolic acid ester, oleuropein. These polyphenolic compounds can be measured in 
foods by established methods.  
Total polyphenols are usually expressed as gallic acid equivalents, but other phenolic compounds 
such as catechin/epicatechin or caffeic acid have also been used for standardisation. This 
standardisation refers to the traditional spectrophotometric measurement of total polyphenols using 
the Folin-Ciocalteau method (Singleton and Rossi, 1965), which is based on reducing capacity. The 
method is not specific for polyphenols because other reducing compounds such as ascorbic acid, 
sugars and proteins will also be included in the quantification, thus leading to an overestimation of the 
actual polyphenol content. The total polyphenol content assessed with this method is not suitable for 
characterisation of polyphenols in foods. 
The Panel considers that polyphenols (e.g. hydroxytyrosol and oleuropein complex) in olive (olive 
fruit, olive mill waste waters or olive oil, Olea europaea L. extract and leaf) can be characterised by 
their content of hydroxytyrosol and its derivatives (e.g. oleuropein complex). 
The Panel considers that the food constituent, polyphenols in olive (olive fruit, olive mill waste waters 
or olive oil, Olea europaea L. extract and leaf) standardised by their content of hydroxytyrosol and its 
                                                     
5  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
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derivatives (e.g. oleuropein complex), which is the subject of the health claims, is sufficiently 
characterised. 
2. Relevance of the claimed effect to human health (ID 1639) 
The claimed effect, which is eligible for further assessment, relates to the maintenance of normal 
blood HDL-cholesterol concentrations. The proposed target population is the general population.  
High-density lipoproteins (HDL) act as cholesterol scavengers and are involved in the reverse 
transport of cholesterol in the body (from peripheral tissues back to the liver). Conversely, 
low-density lipoproteins (LDL) carry cholesterol from the liver to peripheral tissues, including the 
arteries.  
The Panel considers that maintenance of normal HDL-cholesterol concentrations (without increasing 
LDL-cholesterol concentrations) is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect (ID 1639) 
In its earlier opinion (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2011) the 
Panel took into account that the results from the two human intervention studies provided (Covas et 
al., 2006; Marrugat et al., 2004) were inconsistent, and that no evidence for a biologically plausible 
mechanism by which olive oil polyphenols could exert the claimed effect was provided. 
In the framework of further assessment, nine human intervention and four animal studies were 
provided. In five of the human intervention studies (Estevez-Gonzalez et al., 2010; Haban et al., 2004; 
Perona et al., 2011; Ruano et al., 2007; Violante et al., 2009), as well as in one animal study (Mangas-
Cruz et al., 2001), the content of hydroxytyrosol or its derivatives (e.g. oleuropein complex) in the 
olive oils administered in the studies was not reported. In one human intervention study (Susalit et al., 
2011), designed to assess the effects of olive polyphenols on blood pressure, 23 % of subjects were 
withdrawn from the study due to stopping rules related to the primary outcome of the study, which 
might have led to selection bias through breaking randomisation with respect to blood lipid outcomes. 
Two human intervention studies described in one publication (Perrinjaquet-Moccetti et al., 2008) with 
10 subjects per group each, which showed no effect on HDL-cholesterol concentrations, were likely 
to have been underpowered to detect a significant effect of polyphenols in olive on blood 
HDL-cholesterol concentrations. Another intervention study (Weinbrenner et al., 2004) was of a 
duration of four days, which does not allow conclusions to be drawn on a sustained effect of 
consumption of polyphenols in olive on changes in blood HDL-cholesterol concentrations, and in one 
cross-over study (Vissers et al., 2001) and a study in rabbits (Gonzalez-Santiago et al., 2006) no 
baseline measurements were taken. The Panel considers that no conclusions can be drawn from these 
studies for the scientific substantiation of the claim.  
The remaining animal studies assessed the effect of hydroxytyrosol on blood lipid concentrations in 
male Wistar rats (Fki et al., 2007; Jemai et al., 2008). The Panel considers that results from rat studies 
cannot be extrapolated to humans because of differences in lipid metabolism between these two 
species, and considers that no conclusions can be drawn from these animal studies for the scientific 
substantiation of the claim.  
The Panel notes that no evidence from which conclusions can be drawn for the scientific 
substantiation of the claim, in addition to the Panel’s earlier opinion, was provided. 
The Panel considers that no data were submitted which would require a reconsideration of the 
conclusions expressed in its previous opinion, in which it concluded that the evidence provided was 
insufficient to establish a cause and effect relationship between the consumption of olive oil 
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polyphenols (standardised by the content of hydroxytyrosol and its derivatives) and maintenance of 
normal blood HDL-cholesterol concentrations. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, polyphenols in olive (olive fruit, olive mill waste waters or olive oil, 
Olea europaea L. extract and leaf) standardised by their content of hydroxytyrosol and its 
derivatives (e.g. oleuropein complex), which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect eligible for further assessment relates to the maintenance of normal blood 
HDL-cholesterol concentrations. The target population is the general population. 
Maintenance of normal blood HDL-cholesterol concentrations (without increasing LDL 
cholesterol concentrations) is a beneficial physiological effect. 
 No data were submitted which would require a reconsideration of the conclusions expressed 
in its previous opinion, in which it concluded that the evidence provided was insufficient to 
establish a cause and effect relationship between the consumption of olive oil polyphenols 
(standardised by the content of hydroxytyrosol and its derivatives) and maintenance of normal 
blood HDL-cholesterol concentrations. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 for further assessment 
(No: EFSA-Q-2012-00164). The scientific substantiation is based on the information provided by the 
Member States in the consolidated list of Article 13 health claims, references that EFSA has received 
from Member States or directly from stakeholders and the additional information provided by the 
competent Authority of Germany for further assessment of this claim (available at: 
http://www.efsa.europa.eu/en/topics/topic/article13.htm). 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
6  OJ L12, 18/01/2007 
7  The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8  The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
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consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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GLOSSARY AND ABBREVIATIONS 
HDL  High-density lipoproteins 
LDL  Low-density lipoproteins 
 
 
